M&A Deal Summary |
|
|---|---|
| Date | 2025-03-06 |
| Target | Neurocords - Certain Assets |
| Sector | Medical Products |
| Buyer(s) | Orgenesis |
| Sellers(s) | Neurocords |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2008 |
| Sector | Life Science |
| Employees | 146 |
| Revenue | 1M USD (2023) |
Orgenesis is a pre-clinical cell therapy and regenerative medicine company that is committed to curing Type 1 Diabetes. Orgenesis was founded in 2008 and is based in Germantown, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (Massachusetts) | 1 of 1 |
| Country (United States) | 3 of 3 |
| Year (2025) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-19 |
Tissue Genesis
Houston, Texas, United States Tissue Genesis offers best-in-class, enzyme-derived cell therapy processing solutions using high-performance, point-of-care technology that efficiently extracts adult stem cells from autologous adipose tissue in a fully-enclosed and automated process. Tissue Genesis is based in Houston, Texas. |
Buy | - |
Neurocords offers medical devices. Neurocords is based in Concord, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (Massachusetts) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2025) | 1 of 1 |
